TLSI
NASDAQ · Biotechnology
Trisalus Life Sciences Inc
$5.58
-0.03 (-0.53%)
Open$5.49
Previous Close$5.61
Day High$5.65
Day Low$5.23
52W High$7.95
52W Low$2.20
Volume—
Avg Volume282.5K
Market Cap346.67M
P/E Ratio—
EPS$-0.68
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-22.4% upside
Current
$5.58
$5.58
Target
$4.33
$4.33
$2.61
$4.33 avg
$5.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 74.02M | 47.23M | 45.65M |
| Net Income | -64,306,978 | -3,256,844 | -3,940,718 |
| Profit Margin | -86.9% | -6.9% | -8.6% |
| EBITDA | -43,146,745 | -4,196,050 | -4,663,249 |
| Free Cash Flow | — | -5,024,799 | -4,621,021 |
| Rev Growth | — | +7.1% | +0.6% |
| Debt/Equity | 0.20 | 1.07 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |